Last reviewed · How we verify

Brimonidine 0.33% gel (Br) — Competitive Intelligence Brief

Brimonidine 0.33% gel (Br) (Brimonidine 0.33% gel (Br)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Dermatology.

marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Brimonidine 0.33% gel (Br) (Brimonidine 0.33% gel (Br)) — Galderma R&D. Brimonidine is an alpha-2 adrenergic agonist that constricts blood vessels and reduces redness in the skin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Brimonidine 0.33% gel (Br) TARGET Brimonidine 0.33% gel (Br) Galderma R&D marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor
Dexmetomidine intravenously Dexmetomidine intravenously KAT General Hospital marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor
lofexidine HCl lofexidine HCl USWM, LLC (dba US WorldMeds) marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor
Intranasal dexmedetomidine-esketamine Intranasal dexmedetomidine-esketamine Peking University First Hospital marketed Alpha-2 adrenergic agonist / NMDA receptor antagonist combination Alpha-2 adrenergic receptors; NMDA receptor
Combigan Two Times Daily (BID) Combigan Two Times Daily (BID) Cornerstone Health Care, PA marketed Fixed-dose combination of alpha-2 adrenergic agonist and beta-blocker Alpha-2 adrenergic receptor; beta-1 and beta-2 adrenergic receptors
Sufentanil and dexmedetomidine Sufentanil and dexmedetomidine Obstetrics & Gynecology Hospital of Fudan University marketed Opioid agonist and alpha-2 adrenergic agonist combination Mu opioid receptor and alpha-2 adrenergic receptor
Dexmedetomidine-esketamine combination Dexmedetomidine-esketamine combination Peking University First Hospital marketed Sedative-analgesic combination Alpha-2 adrenergic receptor; NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

  1. USWM, LLC (dba US WorldMeds) · 2 drugs in this class
  2. China International Neuroscience Institution · 1 drug in this class
  3. Icahn School of Medicine at Mount Sinai · 1 drug in this class
  4. Eye Therapies, LLC · 1 drug in this class
  5. Galderma R&D · 1 drug in this class
  6. Guangzhou Women and Children's Medical Center · 1 drug in this class
  7. Derm Research, PLLC · 1 drug in this class
  8. Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
  9. KK Women's and Children's Hospital · 1 drug in this class
  10. American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brimonidine 0.33% gel (Br) — Competitive Intelligence Brief. https://druglandscape.com/ci/brimonidine-0-33-gel-br. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: